Navigation Links
Stereotaxis Reports Improved First Quarter 2012 Financial Results

ST. LOUIS, May 8, 2012 /PRNewswire/ -- Stereotaxis, Inc. (NASDAQ: STXS) today reported financial results for the first quarter ended March 31, 2012. 

Management Comments
Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis, said, "In the first quarter, we continued to capitalize on strong market response to the release of the Epoch™ Solution and robust utilization, realizing a 20% improvement in revenue over the prior year quarter. By quarter end, we had completed 25 upgrades to the Niobe® ES system in existing sites since its launch in December 2011; on pace with our forecast to achieve 40 upgraded sites during the first half of 2012. We expect Niobe® ES system sales will gain momentum throughout the year as we increase reference sites and optimize product value."

"We also improved operating loss by $4.6 million, or 52%, over last year through a combination of top line growth and significantly lower operating spend, which declined 21% year over year," continued Kaminski.

"In order to accelerate our timeline to achieve breakeven, we are executing a plan to reduce operating costs by an additional 15% to 20% without compromising our revenue growth strategies. With the Epoch™ Solution product development behind us, we can focus research dollars on enhancements that ensure market adoption and long-term success of the robotic platform. In addition, we have opportunity for greater efficiencies within our capital sales organization through alignment with our local clinical organization."These strategies, which are built on the successful commercial launch and improving revenue of the Niobe® ES system, position us to reach breakeven while continuing to refine our technology, expand our offering through the Vdrive™ product and leverage our strategic partners in global market opportunities," concluded Kaminski.Financial Results
Revenue for the first quarter 2012 totaled $12.3 million, a 20% increase over the prior year quarterly revenue of $10.2 million and a 6% increase over fourth quarter 2011 revenue of $11.6 million. The Company realized revenue of $2.8 million in Niobe® ES system sales and $2.0 million in Odyssey™ system sales in the first quarter 2012. Recurring revenue in the quarter improved 20% from the year-ago quarter to $7.1 million.The Company generated global new capital orders of $3.0 million in the first quarter, comprised of ten Niobe® ES system upgrades, two Vdrive™ robotic navigation systems and $2.1 million in orders related to the Odyssey™ system. This compares to $7.1 million in global new capital orders in the first quarter 2011 and $3.6 million in the fourth quarter. Ending capital backlog for the first quarter was $16.9 million.

Gross margin in the quarter was $8.5 million, or 69.4% of revenue, versus $7.2 million, or 70.6% of revenue, in the first quarter 2011 and $8.3 million, or 71.4%, in the fourth quarter.

Operating expenses were $12.7 million in the first quarter, down $3.3 million from the year ago period and down $0.2 million sequentially. The decline was primarily attributed to headcount and discretionary spending cuts in the second half of 2011.

Operating loss in the quarter was $(4.2) million, compared to $(8.8) million in the prior year quarter, a 52% improvement and down $0.4 million sequentially, a 9% improvement.

The net loss for the first quarter was $(5.8) million, or $(0.11) per share, compared to a net loss of $(9.5) million, or $(0.17) per share, reported for the first quarter 2011 and $(5.5) million, or $(0.10) per share, in the fourth quarter 2011. The weighted average shares outstanding for the first quarter of 2012 totaled 55.0 million, compared with 54.7 million in the first quarter 2011 and 54.9 million in the fourth quarter. 

Cash burn for the first quarter 2012 was $4.3 million, compared to $11.0 million in the prior year quarter and $14.8 million in the 2011 fourth quarter. The decrease from the prior year quarter is principally due to a smaller net loss and lower working capital while the decline from the 2011 fourth quarter is primarily due to lower working capital and the Company's final repayment of the Biosense Webster advance.

At March 31, 2012, Stereotaxis had cash and cash equivalents of $10.5 million, compared to $14.0 million at December 31, 2011. At quarter end, total debt was $39.5 million, including $14.8 million related to Cowen Healthcare Royalty Partners financing.

"In line with our commitment to capitalize the company, we have entered into definitive agreements to raise approximately $18.5 million in two financing transactions with new and existing institutional investors," stated Kaminski.

The financing consists of $10 million the Company will raise in a private offering of common stock and $8.5 million of unsecured, subordinated convertible promissory debentures, which will be convertible into shares of common stock at all times following the date the Company is required to receive shareholder approval of the transactions. The closing of the transactions is subject to standard and customary closing conditions. Net proceeds from these financings will be used to repay $7 million of the revolving credit facility guaranteed by Alafi Capital and Sanderling Venture Partners, for working capital and general corporate purposes. The Company expects to amend its credit agreement with Silicon Valley Bank to extend its revolving credit facility, which will decrease from $20 million to $13 million after pay down of $7 million of the guaranteed portion, to March 31, 2013, upon closing of the transaction.

Cost Reduction
The Company has announced immediate plans to further lower its cost structure throughout the organization with reductions that do not directly impact top line growth. As a result, it expects to reduce operating spend by an additional 15-20% from first quarter levels by the 2012 fourth quarter.

2012 Milestones
Stereotaxis reaffirmed the following milestones for 2012:

  • Complete additional capital raise and secure extended credit agreement with Silicon Valley Bank
  • Achieve at least 10 new Niobe® ES system sales
  • Complete 40 Niobe® ES system upgrades during the first half of 2012

    Conference Call and Webcast
    Stereotaxis will host a conference call and webcast today, May 8, 2012 at 8:30 a.m. Eastern Time, to discuss first quarter results and operational progress. The dial-in number for the conference call is 1-877-941-1465 for domestic participants and 1-480-629-9772 for international participants.  Participants are asked to call the above numbers 5-10 minutes prior to the start time.  A real-time, listen-only webcast of the conference call will be accessible at in the Investors section under Event Calendar.  Listeners should go to the website at least 15 minutes prior to the live conference call to install any necessary audio software. 

    An audio replay of the call will be available for seven days following the call and can be accessed by dialing 1-800-406-7325 for domestic callers and 1-303-590-3030 for international callers, both using passcode 4536824.  The call also will be available for 90 days at

    About Stereotaxis
    Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. With over 100 patents for use in a hospital's interventional surgical suite, Stereotaxis helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced collaboration of life-saving information. Stereotaxis' core technologies are the Niobe® ES Remote Magnetic Navigation system, the Odyssey™ portfolio of lab optimization, networking and patient information management systems and the Vdrive™ Robotic Mechanical Navigation system and consumables.The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere; the V-Loop™ circular catheter manipulator is currently under regulatory review by the U.S. Food and Drug Administration. For more information, please visit and

    This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to,
    our continued access to capital and financial resources, including our ability to extend our current loan facility and to obtain additional capital through other financing arrangements, in each case on a timely basis and on terms that are acceptable, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, the outcome of various shareholder litigation recently filed against us, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

     2012December 31,
     2011(Unaudited)AssetsCurrent assets:Cash and cash equivalents

    $  10,468,699$   13,954,919Accounts receivable, net of allowance of $704,328 and $667,529 in 2012 and 2011, respectively

    10,293,48111,104,038Current portion of long-term receivables


    7,214,9946,036,051Prepaid expenses and other current assets

    3,416,7403,081,484Total current assets

    31,453,72534,236,171Property and equipment, net

    3,061,6733,323,856Intangible assets, net

    2,204,1952,279,153Long-term receivables

    31,11851,892Other assets

    41,63540,760Total assets

    $  36,792,346$   39,931,832Liabilities and stockholders' equity (deficit)Current liabilities:Current maturities of long-term debt

    $  26,731,186$   21,173,321Accounts payable

    6,003,0945,610,181Accrued liabilities

    5,510,4095,703,166Deferred contract revenue


    313,485125,415Total current liabilities

    46,835,99140,832,389Long-term debt, less current maturities

    12,720,80617,290,531Long-term deferred contract revenue

    602,520634,713Other liabilities

    1,5613,094Stockholders' equity (deficit):Preferred stock,  par value $0.001; 10,000,000 shares authorized at
     2012 and 2011, none outstanding at 2012 and 2011

    --Common stock, par value $0.001; 100,000,000 shares authorized at
     2012 and 2011, 56,372,466 and 55,431,573 shares issued
     at 2012 and 2011, respectively

    56,37255,432Additional paid-in capital

    358,001,453356,729,118Treasury stock, 40,151 shares at 2012 and 2011

    (205,999)(205,999)Accumulated deficit

    (381,220,358)(375,407,446)Total stockholders' equity (deficit)

    (23,368,532)(18,828,895)Total liabilities and stockholders' equity (deficit)

    $  36,792,346$   39,931,832 STEREOTAXIS, INC.STATEMENTS OF OPERATIONS(Unaudited)Three Months Ended
    March 31,20122011RevenueSystem

    $  5,179,505$  4,288,176Disposables, service and accessories

    7,103,7235,936,528Total revenue

    12,283,22810,224,704Cost of revenueSystem

    2,342,4102,184,478Disposables, service and accessories

    1,419,421820,501Total cost of revenue

    3,761,8313,004,979Gross margin

    8,521,3977,219,725Operating expenses:Research and development

    2,825,2073,394,259Sales and marketing

    5,998,7398,338,336General and administration

    3,872,8734,250,269Total operating expenses

    12,696,81915,982,864Operating loss

    (4,175,422)(8,763,139)Other income

    (188,070)20,346Interest income

    1,3633,187Interest expense

    (1,450,783)(810,327)Net loss

    $ (5,812,912)$ (9,549,933)Net loss per common share:Basic and diluted

    (0.17)Weighted average shares used in computing net
    loss per common share: Basic and diluted 


    SOURCE Stereotaxis, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Stereotaxis Market Leadership Reinforced in Core Curriculum and Symposium Presentations at Heart Rhythm 2008
    2. Stereotaxis Receives Commitment to Increase and Extend Its Credit Facility With Silicon Valley Bank
    3. Stereotaxis Announces Public Offering of Common Stock
    4. Stereotaxis Announces Pricing of $26 Million Common Stock Offering
    5. Stereotaxis Announces Underwriters Exercise of Over-Allotment Option
    6. Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter
    7. Stereotaxis System Procedure Featured on NBCs The TODAY Show
    8. Stereotaxis is Notified of the FDA Approval of an Additional Magnetic Irrigated Catheter
    9. Stereotaxis Installs First System in Taiwan
    10. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
    11. Stereotaxis Announces Vdrive(TM), a New Technology for Remote Navigation of Diagnostic Devices
    Post Your Comments:
    (Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
    (Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
    (Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... WI (PRWEB) , ... October 13, 2017 , ... As ... in medicine known as “patient engagement.” The patient is doing more than filling out ... partners. , “There is an increasing emphasis in health care and research on ...
    (Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected ... Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the position ... the end of 2018. Upon assuming the role of President and CEO on January ...
    (Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of ... ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership in ... It also provides a forum to network with elder law attorneys nationwide,” said Somekh. ...
    (Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
    Breaking Medicine News(10 mins):